Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib in LS-SCLC Receiving Concurrent Chemo-radiotherapy
NCT07881705Phase 3Active, not recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelosuppression comparing Trilaciclib + concurrent chemo-radiotherapy with Placebo+ concurrent chemo-radiotherapy (2 arms). Primary endpoints: Duration of severe neutropenia and Incidence of severe neutropenia up to 3.5 months. Started Jun 2026; status: active, not recruiting.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT07881705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07881705.